MorphoSys AG buy mohabbatein
Summary
This prediction ended on 16.07.15 with a price of €74.26. With a performance of 2.03%, the BUY prediction by mohabbatein for MorphoSys AG closed with a slight gain. mohabbatein has 50% into this predictionMorphoSys is a German biopharmaceutical company that develops innovative therapies for the treatment of cancer, autoimmune diseases, and other serious illnesses. The company specializes in developing monoclonal antibodies, which are highly specific and targeted therapies that recognize and bind to specific cancer cells or disease-causing proteins in the body. MorphoSys has a diverse pipeline of products in various stages of development, including several drugs that have shown promising results in clinical trials. The company is listed on the Frankfurt and NASDAQ stock exchanges and has a market capitalization of over $4 billion.
Performance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| MorphoSys AG | -2.232% | -2.232% | 195.990% | -5.247% |
| iShares Core DAX® | -0.205% | 2.949% | 17.330% | 18.203% |
| iShares Nasdaq 100 | 1.613% | 5.877% | 37.451% | 56.281% |
| iShares Nikkei 225® | -0.740% | -1.256% | 11.847% | 5.531% |
| iShares S&P 500 | 0.267% | 3.240% | 29.308% | 46.371% |
Comments by mohabbatein for this prediction
In the thread Morphosys AG diskutieren
Zwischenstopp
Der derzeitige Rücksetzer nach einem negativen Studienergebnis sollte nur mehr ein Luftholen auf dem Weg nach oben sein. Zu viele Pferde hat diese deutsche Biotechperle noch im Stall, als dass man nachhaltig mit niedrigeren Kursen rechnen sollte.
BUY.